FDA Speeds Up Eye Drug for Rare Kids' Disease with Magic Voucher
Published Date: 3/13/2026
Notice
Summary
The FDA just approved EYLEA HD (aflibercept) using a special Rare Pediatric Disease Priority Review Voucher, speeding up its review because it treats a rare childhood illness. This means the company behind EYLEA HD got a fast-track pass, helping kids get medicine sooner. Keep an eye out for more rare disease treatments moving faster thanks to this program!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Faster Approval for Rare Pediatric Drug
If you have a child with the rare pediatric condition treated by EYLEA HD, the FDA approved EYLEA HD (aflibercept) using a Rare Pediatric Disease Priority Review Voucher. The supplemental application was approved on November 19, 2025, and the voucher sped up the review so children can access the medicine sooner.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2026-04887 — Flixbus SE, Flix North America Inc., and Greyhound Lines, Inc.-Control-Pacific Northwest Bus LLC
Flixbus SE, Flix North America, and Greyhound are teaming up to keep control of a new bus company called Pacific Northwest Bus LLC. The government is giving a thumbs-up to this plan, as long as no one objects by April 27, 2026. This move helps these companies keep their bus services running smoothly in the Pacific Northwest without any hiccups.
Next: 2026-04891 — Agency Information Collection Activities; Submission for OMB Review; Comment Request; Fidelity Bonding Issuance
The Department of Labor is asking for public feedback on its plan to collect info about fidelity bonds that protect employers hiring people who might have a tough time getting jobs. This includes folks like recovering addicts, youth without work history, and others. Comments are open until April 13, 2026, and the goal is to make sure the info collection is useful and not too much work for anyone involved.